Sign In
Buy MDGL
$513.43
+0.550 (+0.107%)
At Close: Jun 23, 2026
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
08:00am, Friday, 03'rd Jan 2025
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on
3 Reasons Why Buying Madrigal Pharmaceuticals Today Is a Wise Move
07:46am, Saturday, 23'rd Nov 2024
When a company's shares shoot up 82% in 12 months, investors clearly think it's a good time to be a shareholder -- and that's exactly what's happened to the stock of Madrigal Pharmaceuticals (MDGL 5.5
Madrigal (MDGL) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Friday, 22'nd Nov 2024
Madrigal Pharmaceuticals, Inc. (MDGL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MDGL's 50-day simple moving average broke out
Wall Street Analysts Believe Madrigal (MDGL) Could Rally 26.44%: Here's is How to Trade
11:00am, Monday, 18'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in Madrigal (MDGL). While the effectiveness of this highly sought-after metric is questionable, the posit
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
08:51am, Monday, 11'th Nov 2024
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
1 Growing Biotech Stock to Buy Today With $1,000 and Hold for 5 Years or More
09:30am, Sunday, 10'th Nov 2024
There's a bright future ahead for this company.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
08:21am, Friday, 08'th Nov 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Here's Why Madrigal (MDGL) is a Great Momentum Stock to Buy
01:00pm, Thursday, 07'th Nov 2024
Does Madrigal (MDGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
08:00am, Wednesday, 06'th Nov 2024
CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor confer
Rezdiffra Gains Traction In NASH As Madrigal Pharmaceuticals Targets European Expansion
09:00am, Sunday, 03'rd Nov 2024
Madrigal Pharmaceuticals' Rezdiffra has favorable initial market adoption and FDA approval, positioning it as a foundational therapy for NASH with advanced fibrosis. Broad insurance coverage and allow
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
10:46am, Friday, 01'st Nov 2024
MDGL stock is up as the company reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
Madrigal (MDGL) Reports Q3 Loss, Tops Revenue Estimates
09:20am, Thursday, 31'st Oct 2024
Madrigal (MDGL) came out with a quarterly loss of $4.92 per share versus the Zacks Consensus Estimate of a loss of $6.94. This compares to loss of $5.34 per share a year ago.
Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®
08:00am, Wednesday, 30'th Oct 2024
CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis
Madrigal Pharmaceuticals: Looking To Finally Establish A Position Around The Q3 Earnings
03:42am, Monday, 28'th Oct 2024
Madrigal Pharmaceuticals' Rezdiffra, approved for NASH, shows strong early demand and revenue growth, making Q3 earnings a potential catalyst for stock movement. Despite steep Q2 losses, Madrigal's $1
Madrigal: Why I'm Having Doubts On The Bull Case Ahead Of Q3 Earnings
12:11pm, Thursday, 24'th Oct 2024
Madrigal's Rezdiffra, the first FDA-approved drug for MASH, shows promise but faces competition from GLP-1 drugs and financial challenges in launching in Europe. Despite meeting Phase 3 endpoints and
